Vericel Toekomstige groei
Future criteriumcontroles 4/6
De verwachting is dat Vericel de winst en omzet met respectievelijk 32.4% en 14.9% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 30.9% per jaar.
Belangrijke informatie
32.4%
Groei van de winst
30.92%
Groei van de winst per aandeel
| Biotechs winstgroei | 27.6% |
| Inkomstengroei | 14.9% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 03 Aug 2026 |
Recente toekomstige groei-updates
Recent updates
Narratiefupdate • Jul 31
VCEL: Raised Guidance And Buyback Will Support Stronger Forward Repricing
Analysts have raised their fair value estimate for Vericel stock from $42.00 to $55.00, citing recent price target increases that follow reported MACI performance in Q2, as well as guidance they consider achievable for the second half of the year. Analyst Commentary Recent Street research on Vericel has focused on how current expectations for MACI and the broader MedTech backdrop feed into risk and reward for the stock.
Narratiefupdate • Jul 17
VCEL: Raised Outlook And New Headquarters Will Support Stronger Future Position
Vericel's implied fair value estimate has moved from about $53.88 to $57.14 as analysts adjust their price targets, citing updated expectations around revenue growth, profit margins and sector volatility. What’s in the News for Vericel Vericel approved an amendment to the company’s bylaws to reflect the relocation of its principal executive offices to a new global headquarters at 25 Blue Sky Drive, Burlington, Massachusetts 01803.
Narratiefupdate • Jun 26
VCEL: Strong Q1 Execution And BARDA Contract Will Drive Future Upside
Analysts have raised their fair value estimate for Vericel to $70.00 from $64.00, citing updated assumptions on revenue growth, profit margins, and future P/E, even as some Street targets such as Truist's have recently moved lower. What’s in the News for Vericel Analysts highlighted Vericel’s recent first quarter results, where revenues were reported at 7.6% above expectations and statutory losses were reduced, according to a summary of Wall Street research (source: Zacks / TD Cowen coverage summary).Analyse-artikel • Jun 22
Vericel (VCEL) Stock Could Be 37.3% Undervalued After Earnings Beat And Fund Buying
Vericel (VCEL) has drawn fresh attention after institutional holders such as BlackRock and State Street lifted their positions, and the company reported quarterly earnings per share that came in above market expectations. See our latest analysis for Vericel. Vericel's share price has picked up momentum recently, with a 1-day share price return of 2.48%, 7-day return of 7.05%, and 90-day return of 23.57%. This comes even though the 1-year total shareholder return declined 4.57% and the 5-year...Analyse-artikel • May 09
The Vericel Corporation (NASDAQ:VCEL) First-Quarter Results Are Out And Analysts Have Published New Forecasts
As you might know, Vericel Corporation ( NASDAQ:VCEL ) just kicked off its latest quarterly results with some very...Nieuw narratief • May 02
Expanded Cell Therapy Capacity And Burn Care Franchise Will Drive Multiyear Upside Potential
Catalysts About Vericel Vericel develops and manufactures advanced cell therapies for cartilage repair and severe burn care. What are the underlying business or industry changes driving this perspective?Nieuw narratief • Apr 17
Expanded Cell Therapy Pipeline Will Face Execution Risks Yet Ultimately Support Healthier Business
Catalysts About Vericel Vericel develops and manufactures advanced cell therapies for sports medicine and burn care, including MACI for cartilage repair and Epicel and NexoBrid in burn care. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Jan 04
Vericel: Growth Plans May Have Run Out Of Gas (Rating Downgrade)
Summary Vericel (VCEL) is rated a hold due to inconsistent growth, fluctuating profitability, and limited near-term upside at current valuation. VCEL’s future hinges on scaling MACI, as Epicel and Nexobrid have stalled and face capped demand in niche markets. International expansion and MACI Arthro could drive growth, but execution risks and delayed timelines temper confidence in acceleration. Despite strong cash and no long-term debt, persistent SG&A growth and negative free cash flow highlight challenges in achieving sustainable profitability. Read the full article on Seeking AlphaAnalyse-artikel • Nov 12
There's No Escaping Vericel Corporation's (NASDAQ:VCEL) Muted Revenues Despite A 29% Share Price Rise
Vericel Corporation ( NASDAQ:VCEL ) shares have had a really impressive month, gaining 29% after a shaky period...Analyse-artikel • Jun 16
Does Vericel (NASDAQ:VCEL) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analyse-artikel • May 01
Risks To Shareholder Returns Are Elevated At These Prices For Vericel Corporation (NASDAQ:VCEL)
With a median price-to-sales (or "P/S") ratio of close to 9.6x in the Biotechs industry in the United States, you could...Seeking Alpha • Mar 06
Vericel: Scalable Growth With Strong Margins
Summary Vericel's niche in regenerative medicine is undervalued, with FDA-approved products like MACI, Epicel, and NexoBrid driving steady revenue growth and profitability. The company's strong financials include $167 million in cash, zero debt, and a 16% year-over-year revenue increase, highlighting operational efficiency. MACI's expansion into ankle cartilage repair and a robust pipeline suggest significant future earnings potential, despite current market hesitations. VCEL's strategy focuses on indication expansion and market penetration, aiming for long-term margin growth and reduced vulnerability to high-risk drug development. Read the full article on Seeking AlphaSeeking Alpha • Dec 19
Vericel Corporation: Hard To Justify Current Valuation
Summary Vericel Corporation, specializing in cellular therapies for sports medicine and severe burn care, has seen a 40% rise in its stock recently. Core products include MACI, NexoBrid, and Epicel, with Q3 revenues rising 27% year-over-year to $57.9 million, beating expectations. The company is turning the corner on profitability, but valuations look stretched at current trading levels. An analysis around Vericel follows in the paragraphs below. Read the full article on Seeking AlphaAnalyse-artikel • Nov 09
Vericel Corporation (NASDAQ:VCEL) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Vericel Corporation ( NASDAQ:VCEL ) shares have had a really impressive month, gaining 32% after a shaky period...
Nieuw narratief • Sep 10
MACI And NexoBrid Drive Record Revenues And Profit Growth, Setting Stage For Robust Future Performance
Expansion of MACI and NexoBrid markets driving record revenues, indicating significant future revenue growth.Analyse-artikel • Jul 12
What Vericel Corporation's (NASDAQ:VCEL) P/S Is Not Telling You
With a median price-to-sales (or "P/S") ratio of close to 11.3x in the Biotechs industry in the United States, you...Analyse-artikel • May 11
Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Vericel Corporation ( NASDAQ:VCEL ) just released its first-quarter report and things are looking bullish. Revenues and...Analyse-artikel • Apr 26
It's Unlikely That The CEO Of Vericel Corporation (NASDAQ:VCEL) Will See A Huge Pay Rise This Year
Key Insights Vericel will host its Annual General Meeting on 1st of May Salary of US$790.0k is part of CEO Nick...Analyse-artikel • Mar 02
Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vericel fair value estimate is US$87.12 Vericel is estimated...Analyse-artikel • Feb 02
Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%
Vericel Corporation ( NASDAQ:VCEL ) shareholders would be excited to see that the share price has had a great month...Analyse-artikel • May 05
Vericel Corporation's (NASDAQ:VCEL) Shareholders Might Be Looking For Exit
It's not a stretch to say that Vericel Corporation's ( NASDAQ:VCEL ) price-to-sales (or "P/S") ratio of 9.4x right now...Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 455 | 73 | N/A | N/A | 7 |
| 12/31/2027 | 393 | 47 | N/A | N/A | 8 |
| 12/31/2026 | 336 | 29 | N/A | 98 | 8 |
| 6/30/2026 | 306 | 24 | 62 | 70 | N/A |
| 3/31/2026 | 292 | 21 | 47 | 62 | N/A |
| 12/31/2025 | 276 | 17 | 25 | 52 | N/A |
| 9/30/2025 | 259 | 13 | 20 | 59 | N/A |
| 6/30/2025 | 249 | 7 | -8 | 47 | N/A |
| 3/31/2025 | 239 | 3 | -7 | 58 | N/A |
| 12/31/2024 | 237 | 10 | -6 | 58 | N/A |
| 9/30/2024 | 227 | 4 | -12 | 46 | N/A |
| 6/30/2024 | 215 | 1 | -2 | 43 | N/A |
| 3/31/2024 | 208 | 0 | 2 | 35 | N/A |
| 12/31/2023 | 198 | -3 | 8 | 35 | N/A |
| 9/30/2023 | 185 | -10 | 11 | 32 | N/A |
| 6/30/2023 | 178 | -13 | 13 | 29 | N/A |
| 3/31/2023 | 169 | -17 | 9 | 22 | N/A |
| 12/31/2022 | 164 | -17 | 10 | 18 | N/A |
| 9/30/2022 | 159 | -18 | 14 | 21 | N/A |
| 6/30/2022 | 155 | -16 | 12 | 21 | N/A |
| 3/31/2022 | 158 | -11 | 14 | 22 | N/A |
| 12/31/2021 | 156 | -7 | 21 | 29 | N/A |
| 9/30/2021 | 154 | 0 | 22 | 30 | N/A |
| 6/30/2021 | 152 | 9 | 25 | 31 | N/A |
| 3/31/2021 | 132 | 4 | 19 | 23 | N/A |
| 12/31/2020 | 124 | 3 | 15 | 18 | N/A |
| 9/30/2020 | 118 | 0 | 7 | 9 | N/A |
| 6/30/2020 | 117 | 0 | 10 | 13 | N/A |
| 3/31/2020 | 123 | -12 | N/A | -3 | N/A |
| 12/31/2019 | 118 | -10 | N/A | -7 | N/A |
| 9/30/2019 | 110 | -14 | N/A | -8 | N/A |
| 6/30/2019 | 102 | -18 | N/A | -14 | N/A |
| 3/31/2019 | 95 | -3 | N/A | -1 | N/A |
| 12/31/2018 | 91 | -8 | N/A | 0 | N/A |
| 9/30/2018 | 83 | -13 | N/A | -2 | N/A |
| 6/30/2018 | 75 | -17 | N/A | -9 | N/A |
| 3/31/2018 | 73 | -15 | N/A | -10 | N/A |
| 12/31/2017 | 64 | -17 | N/A | -13 | N/A |
| 9/30/2017 | 57 | -26 | N/A | -23 | N/A |
| 6/30/2017 | 54 | -29 | N/A | -22 | N/A |
| 3/31/2017 | 50 | -31 | N/A | -22 | N/A |
| 12/31/2016 | 54 | -27 | N/A | -20 | N/A |
| 9/30/2016 | 53 | -26 | N/A | -15 | N/A |
| 6/30/2016 | 54 | -23 | N/A | -11 | N/A |
| 3/31/2016 | 54 | -22 | N/A | -11 | N/A |
| 12/31/2015 | 51 | -23 | N/A | -13 | N/A |
| 9/30/2015 | 50 | -20 | N/A | -16 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei VCEL ( 32.4% per jaar) ligt boven de spaarquote ( 3.7% ).
Winst versus markt: De winst van VCEL ( 32.4% per jaar) zal naar verwachting sneller groeien dan de US markt ( 16.8% per jaar).
Hoge groeiwinsten: De winst van VCEL zal naar verwachting de komende 3 jaar aanzienlijk groeien.
Omzet versus markt: De omzet van VCEL ( 14.9% per jaar) zal naar verwachting sneller groeien dan de markt US ( 12.9% per jaar).
Hoge groei-inkomsten: De omzet van VCEL ( 14.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van VCEL naar verwachting over 3 jaar hoog zal zijn
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/10 04:42 |
| Aandelenkoers aan het einde van de dag | 2026/08/10 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Vericel Corporation wordt gevolgd door 20 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Keay Nakae | Ascendiant Capital Markets LLC |
| Michael Gorman | BTIG |
| Caitlin Cronin | Canaccord Genuity |